Opinion|Videos|February 10, 2025
Shared Decision-Making in Tardive Dyskinesia
Panelists discuss how TD treatment can be optimized through individualized approaches that consider patient-specific factors like symptom severity, comorbidities, concurrent medications, and daily routines, utilizing tools like titration kits to carefully adjust VMAT2 inhibitor dosing while monitoring response and tolerability to achieve the best possible outcomes for each patient.
Advertisement
Episodes in this series
Video series above is prompted by the following:
- How can treatment strategies for TD be individualized (eg, titration kits) based on patient-specific factors?
Advertisement
Related to this article
This quiz was created in collaboration with PTCE™.
Pharmacy professionals can leverage LinkedIn to build a professional brand, expand meaningful connections, share expertise, and create opportunities for career growth.
An Italian pharmacy student offers an inside look at pharmacy education in Italy, from admission and coursework to oral exams and professional training.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
The once-nightly drop, previously approved to reverse pupil dilation, met its primary end point in 2 phase 3 trials, with conjunctival hyperemia most common.
Public data may help identify drugs associated with shortages, but hospital inventory and purchasing data could make early-warning tools more useful.
Danielle Roman, PharmD, BCOP, FHOPA, explains how ASCO’s updated breast cancer surveillance guideline links follow-up intensity to recurrence risk and creates opportunities for pharmacist involvement.
Pharmacy students can create greater career optionality by viewing the PharmD as a professional platform rather than a predetermined job title.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
3
FDA Approves Phentolamine Eye Drop for Presbyopia in Adults
4
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
5